RxDoctor Payments Data

Mary Dagen, MD

Family Medicine · Grand Rapids, MINPI 1831341130

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $227,511 of the $265,008 with a category attached, or 85.9%. Novo Nordisk accounts for 65.9% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $103,406, more than ten times the $688 reported in 2019. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$265,008in general payments, 2019–2025

Across 410 payments — averaging $646.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$175K
  • Lilly USA, LLC$90K
  • Bioventus LLC$177
  • Medtronic$148
  • Ironshore Pharmaceuticals Inc.$132
  • Sanofi-aventis U.S. LLC$64
  • plus $85 from 3 others

What the payments were for

  • Consulting fees$6,8153%
  • Speaking & faculty fees$227,51186%
  • Travel & lodging$21,5168%
  • Food & beverage$8,8763%
  • Education$2900%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$265,008 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$20,396
Medicare patients
78
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$128,478
OzempicSemaglutide104$106,938
TrulicityDulaglutide40$44,292
WegovySemaglutide31$40,273
JardianceEmpagliflozin11$8,572
Topiramate357$4,665
Metformin Hcl ErMetformin Hcl95$1,877
Naltrexone Hcl45$1,772
Bupropion Hcl SrBupropion Hcl38$658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$89,754$172,770153 claims
Novo NordiskOzempic, Wegovy$174,649$147,211135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →